The Alberta government, under the Alberta Biosimilars Initiative, is changing the funding of select biologic medications for adult patients on Alberta government sponsored drug plans
Alberta spent more than $238 million in the 2018 to 2019 fiscal year on biologic drugs and these costs are increasing every year. Costs per patient for originator biologics can be more than $25,000 per patient per year, with biosimilar versions costing up to 50 per cent less than originator biologics.
Alberta is implementing the Biosimilar Initiative which will save approximately $30 million annually that can be invested into other health care services for Albertans.
For more information: Click HERE